Vacunas contra el SARS-CoV-2: ¿son una realidad para América Latina?

Torres, Alfredo G

Torres, Alfredo G.

Torres AG; Department of Microbiology and Immunology, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA. altorres@utmb.edu.

Biomedica ; 40(3): 424-426, 2020 09 01.

Article in Spanish | MEDLINE | ID: covidwho-840381

Subject(s)

Betacoronavirus/immunology; Coronavirus Infections/prevention & control; Pandemics/prevention & control; Pneumonia, Viral/prevention & control; Viral Vaccines; Adenoviridae/genetics; Adenoviridae/immunology; Antibodies, Neutralizing/biosynthesis; Antibodies, Neutralizing/immunology; Antibodies, Viral/biosynthesis; Antibodies, Viral/immunology; Antigens, Viral/immunology; Betacoronavirus/genetics; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Epitopes/immunology; Humans; Immunogenicity, Vaccine; Latin America; RNA, Messenger/administration & dosage; RNA, Messenger/genetics; SARS-CoV-2; Spike Glycoprotein, Coronavirus/genetics; Spike Glycoprotein, Coronavirus/immunology; T-Cell Antigen Receptor Specificity; United States; Vaccines, Attenuated/immunology; Vaccines, Inactivated/immunology; Vaccines, Synthetic/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: Spanish Journal: Biomedica Year: 2020 Document Type: Article Affiliation country: Biomedica.5826

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google